FDA Grants Orphan Drug Designation to Felzartamab for Kidney Transplant Recipients

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

Related Keywords

United States ,American ,Uptal Patel ,Drug Administration For Primary Membranous Nephropathy ,American Society Of Nephrology Kidney Week ,Orphan Drug Designation ,Human Immunology Biosciences ,American Society ,Nephrology Kidney Week ,Breakthrough Therapy Designation ,Bio Receives ,Drug Designation ,Antibody Mediated Rejection ,Kidney Transplant ,Bio Announces Positive Phase ,Primary Membranous ,Drug Administration ,Primary Membranous Nephropathy ,